A Subcutaneously Delivered Anti-IGF-1R for Thyroid Eye Disease (TED)
Lonigutamab is a subcutaneously delivered anti-IGF-1R currently being evaluated in a Phase 1 study for Thyroid Eye Disease – a greater than $4 billion estimated market opportunity – with potential implications for efficacy, safety, and administration benefits for patients relative to the current standard of care.